Title of Invention

"A CHEMOENZYMATIC PROCESS FOR STEREOSELECTIVE PREPARATION OF BOTH (R) AND (S) ENATIOMERS OF 3-HYDROXY-3-(2-THIENYL) PROPANENITRILE"

Abstract A chemoenzymatic process for the stereoselective preparation of both the (R) and (S) enantiomers of 3-hydroxy-3-(2-thienyl) propanenitrile The invention relates to a chemoenzymatic process for the stereoselective preparation of both the (R) and (S) enantiomers of 3-hydroxy-3-(2-thienyl) propanenitrile. These optically pure key intermediates were prepared by enzymatic resolution of (±)3-hydroxy-3-(2-thienyl) propanenitrile both by transesterification and by hydrolysis reaction which were then transformed to both enantiomers of duloxetine. The alcohol and the ester formed in the kinetic resolution were separated by column chromatography. The enantiomeric purities of the compounds were in excess of 99%.
Full Text Field of the invention
The present invention relates to a chemoenzymatic process for stereoselective preparation of both R and S enantiomers of 3-hydroxy-3-(2-thienyl) propanenitrile (1).
This invention particularly relates to a chemoenzymatic process for the stereoselective preparation of both the enantiomers of 3-hydroxy-3-(2-thienyl) propanenitrile (2) a key intermediate for the synthesis of antipsychic drug duloxetine. Background of the invention
Duloxetine and related class of compounds like fluoxetine, tomoxetine etc., are important for treating psychiatric disorders. Fluoxetine is a selective inhibitor of serotonin in serotonergic neurons, tomoxetine and nisoxetine are selective inhibitors of norepinephrine in noradrenergic neurons while duloxetine is a dual inhibitor of serotonin and norepinephrine reuptake and thus have a better pharmacological profile as an antidepressant drug (EP 273658, 1988; Chem. Abstr., 1988, 109, 170224n; Life Sci. 1988, 43, 2049).
Serotonin and norepinephrine neuro transmitters are intimately involved in a number of physiological and behavioral processes, suggesting that duloxetine (ability to produce robust increase of extra cellular serotonin and norepinephrine levels) is not only a highly efficient antidepressant agent for treating psychiatric disorders but also can be used for treating other symptoms like alcoholism, urinary incontinence, fatigue, stroke, intestinal cystitis, obsessive compulsive disorder, panic disorder, hyperactivity disorder," sleep disorder, sexual dysfunction etc.
Duloxetine having one chiral center can exist in two isomeric forms. In view of the different pharmacological activities displayed by individual enantiomers. differences in metabolic behaviour and importance to provide enantiomerically pure forms as drugs, the preparation of this drug in enantiomerically pure form is highly desirable.
Duloxetine has the basic structural skeleton of 3-amino-propanol and retrosynthetic synthetic strategy reveals that enantiomerically pure 3-hydroxy-3-(2-thienyl) propanenitrile (P-hydroxy nitrile) (1) should be an excellent chiral building block for the synthesis of the target molecule. In the literature, there are only few reports for the synthesis of duloxetine in optically pure form, one by employing

complexed-LAH for asymmetric reduction of the Mannich base {Tetrahedron Lett. 1990, 31, 7101) and other by lipase mediated resolution of 3-chloro-l-(2-thienyl)-l-propanol {Chirality 2000,12, 26).
(Formula Removed)
Objects of the invention
The main object of the invention is to provide a chemoenzymatic process for the stereoselective preparation of both the enantiomers of 3-hydroxy-3-(2-thienyl) propanenitrile (1) which are optically pure intermediates for the synthesis of both enantiomers of duloxetine in high enantiomeric excess.
In the drawings accompanying this specification represents enzymatic
resolution of 3-hydroxy-3-(2-thienyl) propanenitrile via lipase mediated
transesterification of 3-hydroxy-3-(2-thienyl) propanenitrile (1) and lipase mediated
hydrolysis of 3-acetyloxy-3-(2-thienyl) propanenitrile (2) to afford optically pure
hydroxy nitrile and its corresponding acetate.
Summary of the invention
Accordingly the present invention provides a chemoenzymatic process for the
stereoselective preparation of both R and S enantiomers of 3-hydroxy-3-(2-
thienyl)propanenitrile which consists of stereoselectively reacting 3-hydroxy-3-(2-
thienyl)propanenitrile dissolved in solvent with an acetylating agent selected from the
group consisting of vinyl acetate or isopropenyl acetate using lipase from the group
consisting of Pseudomonas cepacia to produce (R)-3-acetoxy-3-(2-
thienyl)propanenitrile and (S)-3-hydroxy-3-(2-thienyl)propanenitrile, separating the
(R)-3-acetoxy-3-(2-thienyl)propanenitrile and (S)-3-hydroxy-3-(2-
thienyl)propanenitrile obtained, stereoselectively hydrolyzing (R )-3-acetoxy-3-(2-thienyl)propanenitrile or its racemic mixture dissolved in solvent with a lipase as defined above in a phosphate buffer solution having pH 7.2 to produce (R)-3-hydroxy-3-(2-thienyl)propanenitrile or a mixture of (R)-3-hydroxy-3-(2-thienyl)propanenitrile and (S)-3-acetoxy-3-(2-thienyl)propanenitrile, separating the (R)-3-hydroxy-3-(2-thienyl)propanenitrile and (S)-3-acetoxy-3-(2-thienyl)propanenitrile, thus obtained.
In one embodiment of the invention, recycling is not required for the products
obtained by kinetic resolution since the enantiomeric excess is >99%.
In another embodiment of the invention, the acetylating agent is selected from the group consisting of vinyl acetate or isopropenyl acetate.
In yet another embodiment of the invention, the acetylation of the cyanohydrin is done in the presence of a lipase in a solvent.


In a flirther embodiment of the invention, the solvent is selected from the group
consisting of diisopropyl ether, toluene, hexane, dioxane, chloroform, t-butylmethyl
ether, diethyl ether, tetrahydrofuran, acetonitrile and acetone.
In yet another embodiment of the invention, the lipase used is selected from the
group consisting of Pseudomonas cepacia lipase immobilized on modified ceramic
particles (PS-C), Pseudomonas cepacia lipase immobilized on diatomite (PS-D),
Psedomonas cepacia (PS), Porcine pancreas lipase (PPL), Candida cylindracea lipase
(CCL), Candida rugosa lipase (CRL) and lipase immobilized from Mucor miehei
(Lipozyme).
Detailed description of the invention
The present invention provides an enzymatic process for the stereoselective
preparation of both the enantiomers of 3-hydroxy-3-(2-thienyl) propanenitrile (1) , a
key intermediate for the synthesis of both enantiomers of duloxetine which comprises
of reacting the cyanohydrin with acetylating agent and hydrolysis of acetyloxy nitrile in
the presence of lipase followed by separation of acetate and alcohol obtained
employing column chromatography. The 3-hydroxy-3-(2-thienyl) propanenitrile (1)
was selectively acetylated with vinyl acetate, isopropenyl acetate in the presence of
Upases while 3-acetyloxy-3-(2-thienyl) propanenitrile (2) was selectively hydrolyzed in
phosphate buffer in the presence of the Upases.
The alcohol and the ester formed in the kinetic resolution were separated by
column chromatography. The enantiomeric purities of the compounds were determined
by HPLC employing a chiral column (OJ-H). Absolute configurations were
preliminarily presumed to be R for acetate and S for alcohol (in the transesterification
reaction) by the empirical rule for the enantiopreference of the lipase and then later
confirmed from the optical rotation values of their corresponding aminoalcohols
(Chirality 2000,12, 26).
The process of the present invention is illustrated below:
1. Racemic 3-hydroxy-3-(2-thienyl)propanenitrile (1) was acetylated enzymatically
employing different acetylating agents and various Upases in different solvents
2. Acetylating agents such as vinyl acetate and isopropenyl acetate were used for
acetylation.
3. Different Upases like Pseudomonas cepacia lipase immobilized on modified
ceramic particals (PS-C), Pseudomonas cepacia lipase immobilized on diatomite (PSD),
Psedomonas cepacia (PS), porcine pancreas lipase (PPL), Candida cylindracea
lipase (CCL), Candida rugosa lipase (CRL), lipase immobilized from Mucor miehei
(Lipozyme) were screened for the enzymatic transesterification process.
4. Various solvents like diisopropyl ether, toluene, hexane, dioxane, chloroform, tbutylmethyl
ether, diethyl ether, tetrahydrofuran, acetonitrile and acetone were
employed.
5. Racemic 3-acetyloxy-3-(2-thienyl) propanenitrile (2) was prepared by reaction of
the hydroxy nitrile with acetic anhydride in the presence of pyridine.
6. Racemic 3-acetyloxy-3-(2-thienyl) propanenitrile (2) was hydrolyzed
enzymatically employing various lipases in phosphate buffer solution.
7. In the presence of lipases (R)-3-hydroxy-3-(2-thienyl)propanenitrile was
selectively acetylated, and (R)-3-acetyloxy-3-(2-thienyl)propanenitrile was selectively
hydrolyzed and the thus obtained acetates and alcohols were separated by column
chromatography.
8. The enantiomeric excess was determined by HPLC employing chiral column.
The reaction mechanism is given below:
(Figure Removed)

The following examples are given by way of illustration and they should not be
construed to limit the scope of the present invention.
Example 1
Enzymatic Transesterification of 3-hydroxv-3-(2-thienyl) propanenitrile (1) : To a
solution of 3-hydroxy-3-(2-thienyl) propanenitrile (1) (5 mmol) dissolved in
diisopropyl ether (100 mL), Pseudomonas cepacia lipase immobilized on diatomite
(PS-D) (500 mg) and vinyl acetate (25 mmol) were added successively and incubated at
25°C in an orbital shaker. After 50% completion of the reaction (14 h) as indicated by
HPLC, the reaction mixture was filtered and solvent was evaporated under reduced
pressure. The residue was subjected to column chromatography to separate the acetate
formed and the unreacted alcohol. The optical purity of these compounds were
determined by HPLC. (S)-3-hydroxy-3-(2-thienyl) propanenitrile
(S-l) 42% yield, ee >99%; [α]30
D = -33.5 (c 1, CHC13); IR (Neat) 3475, 3075, 2878,
2251, 1105, 698 cm'1; !H NMR (200 MHz, CDC13) 8 2.82 (dd, 2H, J = 3.0 Hz, J = 6.6
Hz), 3.0 (s, IH), 5.25 (t, IH, J = 5.5 Hz), 6.98 (t, IH, J = 4.9 Hz), 7.05 (d, IH, J = 3.7
Hz), 7.28 (d, IH, J= 4.9 Hz); I3C NMR (75 MHz) d 28.1, 66.0, 117.0, 124.6, 125.6,
127.0, 144.4; Mass (El) 153, 127, 113, 85.
(.R)-3-acetyloxy-3-(2-thienyl) propanenitrile (R-2) 43% yield, ee >99%, [α]30
D
= +83.6 (c 1, CHC13); IR (Neat) 3114, 2910, 2800, 2243, 1734, 1216 cm-1; !H NMR
(200 MHz, CDC13) δ 2.10 (s, 3H), 2.94 (d, 2H, J = 6.7 Hz), 6.20 (t, IH, J = 6.7 Hz),
6.97 (t, IH, J = 3.8 Hz), 7.1 (d, IH, 3.0 Hz), 7.3 (d, IH, J = 5.9 Hz); Mass (El) 195,
154,137,114,85,43.
Example 2
Hydrolysis of 3-acetyloxv-3-(2-thienyl) propanenitrile (2) : To a solution of 3-
acetyloxy-3-(2-thienyl) propanenitrile (5 mmol) in 3 mL of acetone was added
phosphate buffer pH = 7.2 and Pseudomonas cepacia lipase immobilized on diatomite
(PS-D) (500 mg) and incubated at 25°C in an orbital shaker. After 50% completion of
the reaction (16 h) as indicated by HPLC, the reaction mixture was filtered and the
filtrate was extracted with ethyl acetate and organic solvent was evaporated under
reduced pressure to leave a residue. The residue was subjected to column
chromatography to separate the unreacted acetate and the alcohol formed. The optical
purity of these compounds were determined by HPLC.
Yield of (R)-3-hydroxy-3-(2-thienyl) propanenitrile (R-1) 42%, ee >99%; [α]30
D
= +32.0(cl, CHCl3);
Yield of (S)-3-acetyloxy-3-(2-thienyl) propanenitrile (S-2) 43%, ee >99%,
[a]30
D = -82.1 (cl.CHCb).
Example 3
Chiral HPLC Analysis: HPLC analysis was performed on an instrument that
consisted of a Shimadzu LC-6A system controller, SPD-6A fixed wavelength UV
monitor as detector, FCV-100B fraction collector and chromatopac C-R4A data
processor as a recording integrator. Analyses were performed by employing chiral
column (Chiralcel OJ-H, Daicel) with hexane: isopropanol (85:15) as the mobile phase
at a flow rate of 0.75 mL/min and monitored at UV 254 nm. Racemic acetate was
prepared by treating its corresponding hydroxy nitrile with acetic anhydride in the
presence of pyridine as an authentic sample for comparision on HPLC.
The main advantages of the present invention are:
Vicinal cyanohydrins or 1,2-cyanohyrins are important and versatile compounds
in organic synthesis as these hydroxy nitriles in optically pure form provides a number
of opportunities for synthetic manipulations leading to a wide range of chiral synthons
like amino alcohols, hydroxy amides, hydroxy esters, hydroxy acids etc., by employing
simple methods. Moreover, thiophene can serve as a masked alkyl chain or masked acid
group making it more useful intermediate for synthesis chirally pure compounds of
biological importance.
In this process chiral 1,2-cyanohydrin has been obtained by lipase mediated
resolution of the racemate by transesterification as well as hydrolysis in high
enantiomeric excess.





We claim:
1. A chemoenzymatic process for the stereoselective preparation of both R and S enantiomers of 3-hydroxy-3-(2-thienyl)propanenitrile which consists of stereoselectively reacting 3-hydroxy-3-(2-thienyl)propanenitrile dissolved in solvent with an acetylating agent selected from the group consisting of vinyl acetate or isopropenyl acetate using lipase from the group consisting of Pseudomonas cepacia to produce (R)-3-acetoxy-3-(2-thienyl)propanenitrile and (S)-3-hydroxy-3-(2-thienyl)propanenitrile, separating the (R)-3-acetoxy-3-(2-thienyl)propanenitrile and (S)-3-hydroxy-3-(2-thienyl)propanenitrile obtained, stereoselectively hydrolyzing (R )-3-acetoxy-3-(2-thienyl)propanenitrile or its racemic mixture dissolved in solvent with a lipase as defined above in a phosphate buffer solution having pH 7.2 to produce (R)-3-hydroxy-3-(2-thienyl)propanenitrile or a mixture of (R)-3-hydroxy-3-(2-thienyl)propanenitrile and (S)-3-acetoxy-3-(2-thienyl)propanenitrile, separating the (R)-3-hydroxy-3-(2-thienyl)propanenitrile and (S)-3-acetoxy-3-(2-thienyl)propanenitrile thus obtained.
2. A process as claimed in claim 1, wherein the solvent is selected from the group consisting of diisopropyl ether, toluene, hexane, dioxane, chloroform, t-butylmethyl ether, diethyl ether, tetrahydrofuran, acetonitrile and acetone.
3. A process as claimed in claim 1, wherein the Pseudomonas cepacia lipase is immobilized on modified ceramic particles or on diatomite, porcine pancreas lipase, Candida cylindracea lipase, Candida rugosa lipase or lipase from Mucor miehei which is immobilized.
4. A chemoenzymatic process for the stereoselective preparation of both R and S enantiomers of 3-hydroxy-3-(2-thienyl) propanenitrile substantially as herein describe with reference to examples accompanying this specification.

Documents:

497-DEL-2003-Abstract-(02-01-2009).pdf

497-del-2003-abstract.pdf

497-DEL-2003-Claims-(02-01-2009).pdf

497-DEL-2003-Claims-(25-02-2009).pdf

497-del-2003-claims.pdf

497-del-2003-complete specification (granted).pdf

497-DEL-2003-Correspondence-Others-(02-01-2009).pdf

497-DEL-2003-Correspondence-Others-(12-01-2009).pdf

497-DEL-2003-Correspondence-Others-(25-02-2009).pdf

497-del-2003-correspondence-others.pdf

497-del-2003-correspondence-po.pdf

497-del-2003-description (complete)(25-02-2009).pdf

497-DEL-2003-Description (Complete)-(02-01-2009).pdf

497-del-2003-description (complete).pdf

497-DEL-2003-Form-1-(25-02-2009).pdf

497-del-2003-form-1.pdf

497-del-2003-form-18.pdf

497-DEL-2003-Form-2-(25-02-2009).pdf

497-del-2003-form-2.pdf

497-DEL-2003-Form-3-(02-01-2009).pdf

497-del-2003-form-3.pdf

497-DEL-2003-Petition-137-(12-01-2009).pdf


Patent Number 233618
Indian Patent Application Number 497/DEL/2003
PG Journal Number 20/2009
Publication Date 15-May-2009
Grant Date 31-Mar-2009
Date of Filing 27-Mar-2003
Name of Patentee COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
Applicant Address RAFI MARG, NEW DELHI-110 001,INDIA
Inventors:
# Inventor's Name Inventor's Address
1 AHMED KAMAL CHEMICAL TECHNOLOGY,HYDERABAD-500 007 INDIA
2 GOLLAPALLI BHASKER RAMESH KHANNA CHEMICAL TECHNOLOGY,HYDERABAD-500 007,INDIA
3 RONDLA RAMU CHEMICAL TECHNOLOGY,HYDERABAD-500 007,INDIA
4 MADDAMSETTY VENKATESWARA RAO CHEMICAL TECHNOLOGY,HYDERABAD-500 007,INDIA
PCT International Classification Number C07D 261/003
PCT International Application Number N/A
PCT International Filing date
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 02/05508 2002-12-16 Ice Land